Attendee search 

Shire is an Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with a large operational base in the United States, its brands and products include Vyvanse, Adderall XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, VPRIV, Firazyr and Dermagraft. 

Shire is currently interested in several therapeutic areas for business development opportunities. The company is most interested in the following products: rare disease therapeutics, pre-clinical to on the market; neuroscience therapeutics, on the market; gastrointestinal, on the market; ophthalmology, post proof-of-concept; and hematology; post proof-of-concept.

Marvao Medical is an early stage medical device company founded in 2006 to develop and commercialize products that reduce the incidence of catheter related bloodstream infections. Our first 2 product lines target a $1B global market opportunity. The first product line is now FDA cleared and is being evaluated at 3 centers in the US with very positive results. We are seeking to raise funds in mid/late 2015 to support full commercialization of this product which will enable the company to become highly profitable in early 2017.

Tangen Biosciences is an early stage diagnostic instrument company that has developed a group of novel technologies that together enable rapid, portable, lab-free, and very low cost molecular diagnostics at the point of care.   

The Tangen platform will amplify and detect specific nucleic acid sequences obtained from a variety of source samples, including clinical specimens such as blood, tissue and sputum, as well as environmental samples obtained from water, soil or food, for example.  The first application of the Tangen platform is the detection and diagnosis of Tuberculosis using DNA extracted from sputum samples, using the Tangen Sputum Processing assay kit

Cynvenio has developed a new LiquidBiopsy technology to sequence the DNA of tumor cells isolated from peripheral blood. Key applications include longitudinal patient monitoring throughout the cancer care cycle, the detection of resistance mutations, and providing physicians with accurate molecular evidence to select the best targeted therapy for a given patient.

Cynvenio's technology can be accessed as a CLIA lab service, or  can be installed and operated inside hospital labs and cancer research centers. Cynvenio's lab has been CLIA certified since 2013 and LiquidBiopsy system deployments began in the second half of 2014.

The HudsonAlpha Institute for Biotechnology

The HudsonAlpha Institute for Biotechnology is a Genomic focused Institute located on a 152-acre bio-medical research campus in Huntsville, Alabama whose mission is to translate scientific breakthroughs in the laboratory into real-world benefits that have a profound impact on people’s lives.

HudsonAlpha BioVentures Philanthropic Fund

•       Specific Philanthropic Fund - part of the HudsonAlpha Foundation a tax-exempt, 501(c) 3 non-profit organization.

•       All investments to the Fund are tax-deductible

•       Fund goal is $50 million

•       Targeted toward donors seeking to make a long-term impact in human health and make a difference for thousands, even millions, of people suffering from serious disease.

Option 1

HudsonAlpha Foundation invests funds in new or established companies and scientific discoveries. Foundation will have an equity stake and receive a ROI, as companies are successful. The return is reinvested into other companies and HudsonAlpha to further its mission and goals – the multiplier effect.

Option 2

HudsonAlpha Foundation will fund promising intellectual property emanating from HudsonAlpha laboratories.

Option 3

HudsonAlpha Foundation provides grant funding to companies who are relocating to or expanding on the HudsonAlpha campus.

All investors/donors will have an opportunity to invest in the future in any and all companies and will be informed regularly on the progress of these companies

Small biotechnology companies are developing half of all future medicines, some of which may not reach patients due to lack of funding from traditional investors.

Although health-related charities received more than $31B in contributions in 2013, many of the charities which support research do not work with for-profit biotech companies. They predominantly fund academic and non-profit institutions which typically conduct early research and discover around 10% of new medicines (for-profit companies discover the remaining 90%).

Impatient is a new kind of health-related charity. We will only fund medical trials with small biotech companies.  

Our scientific advisors will select promising, unfunded, medical treatments. You choose which treatment to support and 100% of your donation is spent on testing.

If the treatment is successful, 100% of the future royalty that Impatient receives from the biotech company will support access to new medicines for people who cannot afford them.